AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Insight Molecular Diagnostics Inc. Director's Dealing 2015

Dec 30, 2015

34238_dirs_2015-12-30_5696ca98-d98f-44be-8225-87a07e750de2.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: OncoCyte Corp (OCX)
CIK: 0001642380
Period of Report: 2015-12-30

Reporting Person: MECHEM KRISTINE C. (VP of Marketing)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Option to Purchase Common Stock	$3.16	2025-08-03	Common Stock (100000)		Direct

Footnotes

F1: One quarter of the options shall vest upon the completion of 12 months of continuous employment from the date of grant on August 4, 2015 and the balance shall vest in 36 monthly installments upon the completion of each month of continuous employment from the first anniversary of the date of grant.